A Study of SHR-A1811 in Subjects With Ovarian Cancer
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
Trial Details
- NCT ID
- NCT06828354
- Phase
- PHASE3
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- RECRUITING
- Cancer Type
- Ovarian Cancer
- Interventions
- SHR-A1811
- Paclitaxel Injection
- Doxorubicin Hydrochloride Liposome Injection
- Gemcitabine Hydrochloride for Injection
- Topotecan Hydrochloride for Injection
- Locations (sample)
- Wuhan, Hubei, China|30.58333,114.26667
- Jinan, Shandong, China|36.66833,116.99722
Key Eligibility Criteria
- The subjects voluntarily joined the study and signed the Informed consent forms (ICF).
- Measurable disease, as defined by RECIST v1.1.
- The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.
- Life expectancy ≥ 12 weeks.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Ovarian Cancer Trials on Trialify →